Loading

logo

Journal of Clinical and Experimental Hematology

ISSN: 2834-3328

Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/hematol.3.023

Methionine adenosyltransferase 2A (MAT2A) inhibitors as single agents or in combination strategy for cancer therapy 

Yi Kuang1,2, Zhiyong Yu1,2, Feng Zhou1,2,*
  • 1State Key Laboratory of Neurology and Oncology Drug Development, Shanghai, China
  • 2Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China
+ Affiliations - Affiliations

Corresponding Author

Feng Zhou, zhoufeng2@simcere.com;
fengz504@icloud.com

Received Date: November 18, 2024

Accepted Date: December 06, 2024

Citation:

Kuang Y, Yu Z, Zhou F. Methionine adenosyltransferase 2A (MAT2A) inhibitors as single agents or in combination strategy for cancer therapy. J Clin Exp Hematol. 2024;3(1):79-82.


Copyright: © 2024 Kuang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Methylthioadenosine phosphorylase (MTAP)-deletion occurs in about 15% of all cancers. The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was found to elicit synthetic lethality in MTAP-deleted cancers. Here, we commented on a novel MAT2A inhibitor SCR-7952, and discussed the potential of MAT2A inhibitors as single agents or in combination for cancer therapy, including solid tumors and hematologic malignancies. Several MAT2A inhibitors with high efficacy and selectivity have been discovered. And MAT2A inhibitors synergize strongly with protein arginine N-methyltransferase 5 (PRMT5) inhibitors, taxanes, platinum, topoisomerase inhibitors, and antibody-drug conjugates (ADC). A MAT2A inhibitor IDE397 and the combination strategies with chemotherapies or other targeted therapies are under investigation in clinical. The promising preliminary clinical results demonstrate the potential of MAT2A inhibitors for the treatment of MTAP-deleted tumors. 

Keywords

MAT2A inhibitor, PRMT5, MTAP-deleted cancer, Drug combination

Recommended Articles

Detection of some synthetic cannabinoids (FUB-AMB and AB-FUBINACA) in blood and urine using Gas Chromatography-mass spectrometry liquid–liquid extraction

In recent years, various types of synthetic cannabinoids have become widely distributed and are causing social and health problems in most parts of the world. Synthetic cannabinoids are currently the largest group of new psychoactive substances. Those that have been subjected to legal control are replaced by newer controlled and uncontrolled substances.

Harnessing innovation for the future of breast cancer management

Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancerrelated mortality in women worldwide. Incidence rates continue to rise globally. Breast cancer encompasses a heterogeneous group of tumors with varying molecular features, clinical behaviors, and responses to therapy. While survival rates have improved, challenges persist such as invasive cancers, recurrent metastatic disease, and mortality among subgroups.

A scoping review of outcome measures in ovarian cancer clinical trials

The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.

Significance of BRCA genetic testing for preoperative breast cancer patients

Examining BRCA mutations in preoperative breast cancer patients is very important when selecting a surgical procedure. Although there are advantages and disadvantages associated with knowing about the presence of genetic mutations, including for the patient’s family, there are many benefits for the patient. BRCA genetic testing should be recommended for patients who are strongly suspected of being positive for a BRCA mutation. 

Molecular signatures of aggressive pediatric liver cancer

Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer.

Full Text
Cite
Download PDF
Author Information X